Vaccines for Papillomavirus (HPV) Infection
C. Rodríguez-Cerdeira*, 1, A. Alba2
Identifiers and Pagination:Year: 2009
First Page: 129
Last Page: 132
Publisher Id: TODJ-3-129
Article History:Received Date: 11/02/2009
Revision Received Date: 16/02/2009
Acceptance Date: 16/02/2009
Electronic publication date: 29/10/2009
Collection year: 2009
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Prophylactic HPV vaccination of both quadrivalent and bivalent vaccines has already been approved in Spain and is gaining popularity among Spanish women. Other European countries show similar trends.
With the use of vaccines against HPV, especially the tetravalent vaccine, in the short or medium-term there will be a lower rate of abnormal cytological results in vaccinated women, which is based on the expected preventive potential, which may range between 50 to 70% of the cases. Furthermore, with the use of the vaccine, in combination with present screening programs, we expect to reach a 92% reduction in the annual number of cases of cervical cancer and other associated pathologies in our country.